Hakan Goker, PhD, joined MS Ventures in 2013. Previously, Hakan was a partner at Aescap Venture in Amsterdam which he joined in 2010. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation and financing, in addition to, business and R&D strategy of various companies including Orphazyme-DK, f-Star NL, Protaffin- Austria/UK, Bicycle Therapeutics -UK, Nimbus Discovery -US, Lumavita -CH, Nitec now Horizon Pharma -CH/US, and Egalet -DK. In addition to the UK, US, Benelux and Switzerland, his global investment and deal flow experience includes the geographies of Scandinavia and Asia.
Hakan received his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London.